Navigation Links
NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study
Date:7/24/2009

orm Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to the timing and outcome of regulatory decisions and label approval being sought or that may be obtained with respect to the NDA for Qutenza with the FDA, including the PDUFA date for the NDA; enrollment in, outcomes and interpretation of the results of clinical trials; the timing of the submission of clinical trial data; acceptance of clinical trial data by the FDA in support of regulatory approval; and the tolerability profile and/or benefits of its product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to; positive results in clinical trials may not be sufficient to obtain FDA approval; the FDA may request additional clinical trials or other information prior to granting approval for Qutenza; any regulatory approvals which are received may be limited to certain indications; NeurogesX' product candidates may have unexpected adverse side effects or inadequate therapeutic efficacy or tolerability; and other difficulties or delays in, clinical development of, and obtaining regulatory approval for NeurogesX' product candidates. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission.

    NeurogesX, Inc.                     The Ruth Group
    Stephen Ghiglieri                   Sara Pellegrino (investors)
    Chief Financial Officer             (646) 536-7002
    (650) 358-3310                      spellegrino@theruthgroup.com

                                        Jaso
'/>"/>
SOURCE NeurogesX
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. NeurogesX Receives FDA Orphan Drug Designation for Qutenza(TM) for Treatment of Postherpetic Neuralgia
2. NeurogesX Announces Publication of Phase 3 Data for QUTENZA(TM) (NGX-4010) in Postherpetic Neuralgia (PHN) by The Lancet Neurology
3. NeurogesX Initiates Dosing in Phase 1 Clinical Trial for NGX-1998 Capsaicin Liquid Formulation
4. NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology
5. NeurogesX Announces Preliminary Results from Second Phase 3 Clinical Trial in HIV-DSP
6. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
7. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
8. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
9. Schering-Plough Announces U.S. Filing of Mometasone Furoate/Formoterol Fumarate Combination for the Maintenance Treatment of Asthma
10. Cardica Announces Publication of Pivotal PAS-Port(R) Proximal Anastomosis System Clinical Trial Results
11. Poniard Pharmaceuticals Announces Positive Cardiac Safety Data From Picoplatin Phase 1 Trial Supporting NDA Filing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 2014  A prospective study conducted by the ... has validated the performance of VolparaDensity breast imaging ... volumetrically assessed breast density measurements to breast cancer ... Prevention (DOI: 10.1158/1055-9965.EPI-13-1219), the article, "Automated measurement ... breast cancer risk assessment," was authored by ...
(Date:7/28/2014)... ORLANDO, Fla. , July 28, 2014 /PRNewswire/ ... "Company"), a biopharmaceutical company focused on the development, ... that it has filed definitive proxy materials with ... its 2014 Annual Meeting of Shareholders to be ... a.m., East Standard Time. The record date for ...
(Date:7/28/2014)... 28, 2014  ResMed (NYSE: RMD ), ... treatment of sleep-disordered breathing and other chronic respiratory conditions, ... against Taiwanese medical device manufacturer APEX Medical ... APEX WiZARD 210 and 220 masks.  The judgment was ... Munich , is appealable, and applies throughout Germany.  ...
Breaking Medicine Technology:Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 2Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 3Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 4TNI BioTech, Inc., Files Definitive Proxy Materials; Mails Letter Urging Shareholders to Vote the Proxy Card 2TNI BioTech, Inc., Files Definitive Proxy Materials; Mails Letter Urging Shareholders to Vote the Proxy Card 3ResMed Receives Permanent Injunction against APEX in Germany, Continues Enforcement of Patents in Europe 2
... is the largest barrier to routine HIV testing by ... by Janssen Therapeutics, Division of Janssen Products, LP, in ... belief by most physicians surveyed (93 percent) that HIV ... African-American community, findings suggested that only one-third of all ...
... 1, 2011 Reportlinker.com announces that a ... its catalogue: Sustained Release ... http://www.reportlinker.com/p0581172/Sustained-Release-Injectables-Evolving-Formulations-Improving-Dosing-Regimens ... injectable drugs to increase the duration of ...
Cached Medicine Technology:Stigma Remains a Significant Barrier to Routine HIV Testing by African-American Physicians, Survey Finds 2Stigma Remains a Significant Barrier to Routine HIV Testing by African-American Physicians, Survey Finds 3Stigma Remains a Significant Barrier to Routine HIV Testing by African-American Physicians, Survey Finds 4Sustained Release Injectables: Evolving Formulations, Improving Dosing Regimens 2Sustained Release Injectables: Evolving Formulations, Improving Dosing Regimens 3
(Date:7/28/2014)... Braintree, Massachusetts (PRWEB) July 28, 2014 ... the Summit Provider Exchange technology solution ... office integration efforts and support collaboration with their ... 242 bed acute-care medical center located in New ... 800,000 seasonal visitors with a variety of inpatient ...
(Date:7/28/2014)... News) -- Endurance runners are far more likely to ... according to a new study. The researchers ... warm climates are actually 10 times more likely to ... common sudden death of a young and apparently healthy ... irregular heartbeat, often gets a lot more media attention. ...
(Date:7/28/2014)... July 28, 2014 The Oakwood Foundation ... Birkhill, Wang, Songe and Associates, PC that will benefit ... tomorrows to come. , The HBWS group is ... more than $2.5 million in donations. Through their latest ... for the Oakwood Women’s Healthcare Classic for the next ...
(Date:7/28/2014)... regions in the brain was able to arouse animals ... In the August issue of Anesthesiology , investigators ... with continuous doses of either agent would move, raise ... electrical stimulation delivered to the ventral tegmental area (VTA). ... substantia nigra, did not induce the animals to wake ...
(Date:7/28/2014)... The report, “Blowing Agents Market by Type, ... Forecasts to 2019” defines and segments the global ... the global consumption volume and value. , Browse ... figures spread through 226 Pages and in-depth TOC ... Blowing agents are highly utilized materials as a ...
Breaking Medicine News(10 mins):Health News:Cape Regional Medical Center Chooses Summit Provider Exchange to Connect With NJSHINE and Physician Offices 2Health News:Cape Regional Medical Center Chooses Summit Provider Exchange to Connect With NJSHINE and Physician Offices 3Health News:Heat Stroke a Greater Threat to Endurance Runners Than Heart Problems: Study 2Health News:Stimulation of brain region restores consciousness to animals under general anesthesia 2Health News:Blowing Agents Market is Poised to Reach 452.0 Kilotons at CAGR of 5.8% by 2019 – Report by MarketsandMarkets 2Health News:Blowing Agents Market is Poised to Reach 452.0 Kilotons at CAGR of 5.8% by 2019 – Report by MarketsandMarkets 3Health News:Blowing Agents Market is Poised to Reach 452.0 Kilotons at CAGR of 5.8% by 2019 – Report by MarketsandMarkets 4
... plans are partnering with physician practices to initiate a range ... these programs have resulted in decreased emergency room (ER) use, ... by the Alliance of Community Health Plans (ACHP), are part ... way community health plans partner with providers to improve care. ...
... Risk Factors for,Developing MS, UB Study Shows, ... insufficiency (CCSVI), which has attracted global attention as possibly being ... for the presence of risk factors in subjects who do ... study of 252 volunteers has found an association between CCSVI ...
... HealthDay Reporter , WEDNESDAY, Nov. 30 (HealthDay News) ... drink or doing some last-minute grooming, a large majority of ... distracted while behind the wheel, a new poll shows. ... adults who drive on a regular basis admitted to having ...
... health care workers at risk of 2009 H1N1 infection during ... according to a study published in the December issue of ... the Society of Healthcare Epidemiology of America. ... Prevention (CDC), tracked 63 Southern California health care workers who ...
... , WEDNESDAY, Nov. 30 (HealthDay News) -- Women ... those with other forms of breast cancer to have a ... finds. Swedish researchers examined the family history, pathology reports ... 1980 and 2008. About 40 percent of the women had ...
... About 40 percent of young adults who,ve attempted suicide made ... thoughts and behavior may begin much younger than previously believed, ... ongoing survey, University of Washington researchers asked almost 900 young ... attempts. Nearly 9 percent (78) of the participants said ...
Cached Medicine News:Health News:New report: Community health plans improving care for patients with chronic illnesses 2Health News:New report: Community health plans improving care for patients with chronic illnesses 3Health News:Risk factors for CCSVI are similar to risk factors for developing MS, UB study shows 2Health News:Risk factors for CCSVI are similar to risk factors for developing MS, UB study shows 3Health News:Risk factors for CCSVI are similar to risk factors for developing MS, UB study shows 4Health News:Most U.S. Drivers Engage in 'Distracting' Behaviors: Poll 2Health News:Most U.S. Drivers Engage in 'Distracting' Behaviors: Poll 3Health News:Most U.S. Drivers Engage in 'Distracting' Behaviors: Poll 4Health News:Lobular Breast Cancer Linked to Paternal Cancer History 2Health News:Many Suicidal Teens Make First Try Before High School 2
Inquire...
... non-contact diagnostic lens, doctors have to make a ... high magnification. Now, with the Digital Wide ... can have both in one lens. This ... in a non-contact lens paired with the higher ...
... portability & capability together in this user-friendly, ... desktop maginifcation., ,With its battery powered option, ... meet any individual, education or business environment ... a briefcase from room to room or ...
... can have accurate patient information and secure dictation ... track of patient schedules, manage daily workflow and ... PC handheld device. PhysAssist IQ is a handheld ... does not require physicians to change the way ...
Medicine Products: